Psoriasis drugs dominated the TV pharma ad landscape in March, as Johnson & Johnson’s Tremfya and AbbVie’s Skyrizi secured the top two spots in iSpot.tv’s ad rankings. The two drugs rose up the list ...
AbbVie’s Skyrizi tallied the most TV impressions among pharma brands in July, rising from second in June. The psoriasis treatment achieved a share of voice (SOV) of 4.61% with 2.5 billion impressions.
Investor's Business Daily on MSN
AbbVie Has A New Cash Cow As Humira Bows To Skyrizi In Third-Quarter Beat
AbbVie stock popped Wednesday after the pharma behemoth's new king in immunology finally outpaced its grandfather drug, ...
Two years after AbbVie’s loss of market exclusivity for Humira, those “How it Started and How it’s Going” memes are looking better each quarter for the Illinois drugmaker. On Friday, when AbbVie ...
On Wednesday, AbbVie Inc. (NYSE:ABBV) reported third-quarter adjusted EPS of $3.00, up from $2.95 a year ago, beating the consensus of $2.92. Net revenues reached $14.46 billion, up 3.8%, beating the ...
AbbVie ABBV delivered encouraging second-quarter 2025 results last week, sending a clear message — it is effectively managing its post-Humira transition. The stronger-than-expected sales of newer ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback